Gandhi Mitul D, Agulnik Mark
Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Onco Targets Ther. 2014 Feb 13;7:245-51. doi: 10.2147/OTT.S46933. eCollection 2014.
Squamous-cell cancer of the head and neck is a heterogeneous malignancy with treatment predicated on a multimodality therapy involving surgery, chemotherapy, and radiation. However, this approach results in durable responses in only a subset of patients, and is associated with significant toxicity. In advanced disease, multi-agent platinum-based chemotherapy produces only modest improvements in survival. Increased insight into tumor biology has demonstrated several critical oncogenic pathways offering prospects for targeted therapy that may improve upon the existing treatment strategies. The epidermal growth factor receptor is one such target, and directed therapy with the monoclonal antibody cetuximab has been extensively studied. Lapatinib is an oral agent that targets multiple transmembrane receptors within the epidermal growth factor receptor family, and offers a promising new approach to treatment. This paper reviews the rationale for and clinical activity of lapatinib in squamous-cell cancer of the head and neck.
头颈部鳞状细胞癌是一种异质性恶性肿瘤，其治疗基于包括手术、化疗和放疗在内的多模态疗法。然而，这种方法仅在部分患者中产生持久反应，且伴有显著毒性。在晚期疾病中，多药铂类化疗仅使生存率有适度提高。对肿瘤生物学的深入了解揭示了几条关键的致癌途径，为靶向治疗提供了前景，有望改进现有治疗策略。表皮生长因子受体就是这样一个靶点，针对单克隆抗体西妥昔单抗的定向治疗已得到广泛研究。拉帕替尼是一种口服药物，可靶向表皮生长因子受体家族中的多个跨膜受体，为治疗提供了一种有前景的新方法。本文综述了拉帕替尼用于头颈部鳞状细胞癌治疗的理论依据和临床活性。
